First-in-human study of CEB-01 in retroperitoneal sarcoma

We are proud to announce the publication of our latest clinical results in Annals of surgical oncology, detailing the first-in-human study of CEB-01, a novel biodegradable membrane for the local delivery of SN-38 after tumour resection. This multicenter trial was designed to establish the recommended phase 2 dose (RP2D) while evaluating safety, efficacy, and pharmacokinetics. Key Highlights: ✅ Positive Safety Profile: Demonstrated preliminary efficacy at the RP2D. ✅ Targeted Delivery: Sustained and controlled release of SN-38 for up to 28 days. ✅ Reduced Systemic Exposure: Achieved localized treatment with lower systemic impact compared to intravenous alternatives. The use of CEB-01 after resection of retroperitoneal sarcomas represents an innovative shift in how we address local recurrences. This is an important step in our mission to develop localized, effective solutions for cancer patients. https://pubmed.ncbi.nlm.nih.gov/41998462/ You might also be interested in CEBIOTEX receives approval to initiate a paediatric phase II clinical trial for locally resectable abdominal tumours We are excited to share that the clinical trial to Read more The European Commission awards Cebiotex the Horizon 2020 Seal of Excellence On December 15, Cebiotex received the Seal of Excellence awarded Read more Tech Barcelona - Pier 07 Via Laietana, 26, entresuelo. 08003, Barcelona. [email protected] cebiotex Legal notice Privacy policy About cookies

The release as fetched from its publisher. cebiotex.com ↗